Sec. 2. Research with respect to menopause and mid-life women’s health
859 words·~4 min read·
/bill/118/s/4246/is/section-2·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Part A of title IV of the Public Health Service Act ( 42 U.S.C. 281 et seq. ) is amended by adding at the end the following: The Director of NIH, acting through the Director of the Office of Research on Women's Health, shall coordinate and expand research activities conducted by all institutes, centers, and offices of the National Institutes of Health to develop and implement Federal research programs with respect to— the impact of the symptoms and trajectories of changes across the menopausal transition and the postmenopausal period on women’s physical, mental, behavioral, and cognitive health; and the prevention of related adverse health outcomes among women during the menopausal transition and the postmenopausal period.
In carrying out paragraph (1), the Director of NIH shall award grants to eligible entities to support— biomedical and public health research and innovation in the development of new treatments and diagnostic testing services for perimenopause and acute and chronic menopausal symptoms; and researchers and clinicians engaged in clinical and translational research on menopause and mid-life women’s health. To be eligible to receive a grant under subsection (b), an entity shall meet such criteria as the Director of NIH may establish, and shall be— an accredited entity that offers education to students in various health professions, such as― a teaching hospital; an accredited school of medicine, osteopathic medicine, nursing, or pharmacy, or a physician assistant training program, including a historically Black college or university (as defined by the term part B institution in section 322 of the Higher Education Act of 1965 or described in section 326(e)(1) of the Higher Education Act of 1965) or other minority-serving institutions (as described in section 371(a) of the Higher Education Act of 1965)); a certified behavioral health clinic with an accredited medical or nursing residency program; an accredited public or nonprofit private hospital with an accredited medical or nursing residency program; an accredited nurse practitioner residency program that includes and accredited nursing residency program; or a related accredited program engaged in the care, treatment, or management of menopausal symptoms; an academic research institution or other nonprofit research institution; a small business; or such other entity as the Director of NIH may determine appropriate.
The Director of NIH shall designate, in the Research, Condition, and Disease Categorization, new categories for chronic or debilitating conditions among women, to analyze and coordinate current and future research on menopause, menopausal symptoms, and short-term and long-term effects of such symptoms on mid-life women’s health. The Director of the NIH shall coordinate and expand Federal research programs and activities to study acute and chronic menopausal symptoms, including— vasomotor symptoms; osteoporosis; sarcopenia; temporomandibular disorders; joint and nerve pain; trauma, anxiety, depression, mood disorders, and related mental and behavioral health conditions; short-term memory loss; genitourinary conditions; alopecia; vision or hearing impairments; digestive and metabolic disorders; chronic sleep deficiency, insomnia, and related sleep disorders; and other menopausal symptoms and related conditions, as the Director of NIH determines appropriate.
The Secretary shall expand translational research activities to accelerate translation of Federal research on perimenopause and menopausal symptoms and facilitate equitable delivery of perimenopause and menopause care and related mid-life women’s health services. The Secretary shall expand outreach and engagement activities with accredited schools of medicine, institutions of higher education, and research institutions to support Federal research activities with respect to menopausal symptoms. .
Part A of title III of the Public Health Service Act ( 42 U.S.C. 241 et seq. ) is amended by adding at the end the following: The Secretary shall expand research activities with respect to the severity and duration of menopausal symptoms and related chronic conditions affecting mid-life health outcomes among women, including mental and behavioral health outcomes. In carrying out activities under this section, the Secretary shall coordinate with existing programs and activities of the Department of Health and Human Services.
The Secretary shall expand research, program evaluation, and quality improvement activities to improve health care delivery for the care, treatment, or management of perimenopause and menopausal symptoms and related chronic conditions, including data collection with respect to preventive services that support mid-life health outcomes among women and barriers to care. The Secretary shall establish and maintain a dashboard for the reporting of data on menopausal symptoms and mid-life health outcomes among women gathered through public health surveillance activities with respect to screening, testing, treatment, and prevention services, and the impact of this section and section 404P on such efforts.
The Secretary shall conduct research activities and expand data collection with respect to workplace stressors related to severe acute or chronic menopausal symptoms, physical injury, or other adverse health outcomes among women, including traumatic stress, anxiety, depression, and related mental and behavioral health conditions. The Secretary shall review existing evidence, identify gaps in services, and develop evidence-informed recommendations for related public health interventions and support services.
The Secretary shall develop and implement new interagency research initiatives or programs to address menopausal symptoms. . For the purpose of carrying out sections 404P and 310C of the Public Health Service Act, as added by subsections
(a)and (b), respectively, there are authorized to be appropriated $25,000,000 for each of fiscal years 2025 through 2029.
Connectionstraces to 2
Traces to 2 documents
Citation graph
cites case law
Cites 2Cited by 0 across 0 sources